Effects of poly(ADP-ribose) polymerase inhibition in bladder damage caused by cyclophosphamide in rats

Exp Biol Med (Maywood). 2008 Mar;233(3):338-43. doi: 10.3181/0706-RM-151.

Abstract

It was previously shown that nitric oxide produced by inducible nitric oxide synthase (iNOS) and peroxynitrite are responsible for cyclophosphamide (CP)-induced cystitis. Since endogenous production of peroxynitrite is known to lead to poly(ADP-ribose) polymerase (PARP) activation, in this study, the aim was to evaluate whether the PARP activation pathway is also included in the pathogenesis of CP-induced bladder ulceration in rats. A total of 48 male albino Wistar rats were divided into 5 groups. Group 1 served as control and was given 2 ml saline; four groups received a single dose of CP (200 mg/kg) with the same time intervals. Group 2 received CP only; Group 3, selective iNOS inhibitor 1400W (20 mg/kg); Group 4, peroxynitrite scavenger ebselen (30 mg/kg); and Group 5, PARP inhibitor 3-aminobenzamide (20 mg/kg). CP injection resulted in severe cystitis with continuous macroscopic hemorrhage, strong edema, inflammation, and ulceration. Moreover, bladder iNOS activation and urine nitrite-nitrate levels were dramatically increased. Histologically, 1400W protected bladder against CP damage and decreased urine nitrite-nitrate levels and bladder iNOS induction. Ebselen has shown similar histologic results with 1400W without changing urinary nitrite-nitrate level and iNOS activity. Furthermore in the 3-aminobenzamide group, beneficial effects had also occurred including decreased ulceration. These results suggest that PARP activation involves pathogenesis of CP-induced bladder ulceration. Furthermore, PARP is not only important for ulceration but also for bladder edema, hemorrhage, and inflammation because of broken uroepithelial cellular integrity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biomarkers / metabolism
  • Body Weight / drug effects
  • Cyclophosphamide / pharmacology*
  • Enzyme Inhibitors / pharmacology*
  • Male
  • Nitric Oxide Synthase Type II / antagonists & inhibitors
  • Nitric Oxide Synthase Type II / metabolism
  • Nitrosation
  • Organ Size / drug effects
  • Poly(ADP-ribose) Polymerase Inhibitors*
  • Poly(ADP-ribose) Polymerases / metabolism
  • Rats
  • Rats, Wistar
  • Urinary Bladder Diseases / chemically induced
  • Urinary Bladder Diseases / enzymology*
  • Urinary Bladder Diseases / pathology
  • Urinary Bladder Diseases / prevention & control*

Substances

  • Biomarkers
  • Enzyme Inhibitors
  • Poly(ADP-ribose) Polymerase Inhibitors
  • Cyclophosphamide
  • Nitric Oxide Synthase Type II
  • Poly(ADP-ribose) Polymerases